Alphamab Oncology (HKG:9966)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
9.89
+0.46 (4.88%)
Jan 21, 2026, 4:08 PM HKT
211.01%
Market Cap9.13B
Revenue (ttm)861.24M
Net Income (ttm)255.11M
Shares Out968.57M
EPS (ttm)0.26
PE Ratio36.42
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,908,000
Average Volume1,770,221
Open9.68
Previous Close9.43
Day's Range9.30 - 9.93
52-Week Range3.05 - 15.75
Beta0.49
RSI37.87
Earnings DateMar 27, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 420
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9966
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

Alphamab Oncology's JSKN033 Cleared For Phase 2 Cervical Cancer Trial By Chinese Regulatory Agency

(RTTNews) - Alphamab Oncology's (9966.HK) Investigational New Drug application for a phase 2 clinical trial of JSKN033 as first-line treatment of advanced cervical cancer has been accepted by the Cent...

23 days ago - Nasdaq